



OPEN ACCESS

Short report

A complex DICER1 syndrome phenotype associated with a germline pathogenic variant affecting the RNase IIIa domain of DICER1

Emeli Pontén ¹, Sofia Frisk,^{1,2} Fulya Taylan ^{1,2}, Raquel Vaz,¹ Sandra Wessman,³ Leanne de Kock ⁴, Niklas Pal,⁵ William D Foulkes ⁴, Kristina Lagerstedt-Robinson ^{1,2}, Ann Nordgren ^{1,2}

► Additional material is published online only. To view, please visit the journal online (<http://dx.doi.org/10.1136/jmedgenet-2020-107385>).

¹Department of Molecular Medicine and Surgery (MMK), Karolinska Institute, Stockholm, Sweden

²Clinical Genetics, Karolinska University Hospital, Stockholm, Sweden

³Oncology-Pathology, Karolinska University Hospital, Stockholm, Sweden

⁴Departments of Human Genetics, Oncology, Medicine, McGill University, Montreal, Québec, Canada

⁵Department of Pediatric Oncology, Karolinska University Hospital, Stockholm, Sweden

Correspondence to

Professor Ann Nordgren, Dept of Molecular Medicine and Surgery (MMK), Karolinska Institute, 171 64 Stockholm, Sweden; ann.nordgren@ki.se

KL-R and AN are joint senior authors.

Received 5 August 2020

Revised 10 October 2020

Accepted 12 October 2020

Published Online First 18 November 2020



© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY. Published by BMJ.

To cite: Pontén E, Frisk S, Taylan F, et al. *J Med Genet* 2022;**59**:141–146.

ABSTRACT

Background Germline pathogenic variants in *DICER1* cause DICER1 syndrome, an autosomal dominant, pleiotropic tumour predisposition syndrome with variable expressivity and reduced penetrance for specific dysplastic and neoplastic lesions. Recently, a syndrome with the acronym GLOW (Global developmental delay, Lung cysts, Overgrowth, Wilms tumour) was described in two children with mosaic missense mutations in hotspot residues of the DICER1 RNase IIIb domain.

Methods Whole genome sequencing, exome sequencing, Sanger sequencing, digital PCR and a review of Wilms tumours with *DICER1* RNase III domain mutations were performed.

Results A de novo heterozygous c.4031C>T (p.S1344L) variant in the sequence encoding the RNase IIIa domain of *DICER1* was detected. Clinical investigations revealed a phenotype that resembles the GLOW subphenotype of DICER1 syndrome.

Conclusion The phenotypic overlap between patients with p.S1344L mutation and GLOW syndrome provide clinical support for recent discoveries that RNase IIIa-Ser1344 site mutations impede miRNA-5p biogenesis analogous to *DICER1* hotspot mutations in the RNase IIIb domain. We show that an individual with a heterozygous germline p.S1344L mutation has a severe form of DICER1 syndrome ('DICER1 syndrome plus'), with notable features of intellectual disability, macrocephaly, physical abnormalities, Wilms tumour and a well-differentiated fetal adenocarcinoma of the lung.

INTRODUCTION

The *DICER1* (MIM *606241) gene located at 14q32.13 is important for embryogenesis and early somatic development. Residing in the cytoplasm, the DICER1 protein is an endoribonuclease (RNase) III cleaving double-stranded RNA. The enzyme is crucial for producing miRNAs, as it processes precursor strands (pre-miRNA) whereby two single-stranded miRNA molecules are produced, named by their prime end origin (3p/5p miRNA).¹

DICER1 syndrome (MIM #601200) is an autosomal dominant, pleiotropic tumour predisposition syndrome with variable expression and reduced penetrance of benign and malignant tumours, commonly pleuropulmonary blastoma (PPB), cystic nephroma, Sertoli-Leydig cell tumour and

hyperplastic proliferations such as multinodular goitre. The most frequently observed mechanism underlying tumour formation in DICER1 syndrome is the presence of biallelic alterations that include germline loss of function (LOF) pathogenic variants, combined with somatic in trans mutations in the sequence encoding the hotspot residues of the RNase IIIb domain.^{1,2}

Missense mutations occurring in exons encoding the DICER1 RNase IIIb domain, either involving or adjacent to catalytically active metal-ion binding residues including p.E1705, p.D1709, p.G1809, p.D1810, p.E1813 and p.D1713 are recognised as cancer hotspot loci. Alterations of these RNase IIIb residues cause neomorphic alleles, reported to be functionally equivalent with respect to miRNA biogenesis.² These alterations interfere with the canonical processing of miRNA precursors, resulting in a relative excess of 3p-miRNA and a depletion of 5p-miRNA.³ It has recently been revealed through evolutionary and structural coupling analyses that RNase IIIa-S1344 site is in close proximity to the active cleft of RNase IIIb domain and that a mutation in RNase IIIa-S1344 exhibit the same pattern of 5p-miRNA loss as that resulting from RNase IIIb hotspot mutations.⁴ In 2014, Klein *et al* proposed a new *DICER1* related syndrome with the acronym GLOW (Global developmental delay, Lung cysts, Overgrowth, Wilms tumour), describing two children with mosaic missense hotspot mutations in *DICER1* affecting the RNase IIIb domain. A highly penetrant and severe phenotype has been shown in patients with mosaic^{5,6} or germline⁷ RNase IIIb mutations, compared with patients with classic DICER1 syndrome caused by germline LOF pathogenic variants.

Here, we show evidence that the germline c.4031C>T (p.S1344L) mutation in *DICER1* causes a severe subtype of DICER1 syndrome with intellectual disability (ID), macrocephaly, extensive bilateral lung cysts, early onset of Wilms tumour and well-differentiated fetal lung adenocarcinoma—a clinical spectrum similar to, but distinct from, the phenotype reported in two patients with GLOW syndrome with postzygotic hotspot mutations in exons encoding the RNase IIIb domain.




Figure 1 Patient characteristics. Photographs of the patient at 10.5 years of age showing (A) posterior ear pits of left helix, (B) a high, broad, furrowed forehead, mild hypertelorism, short, upturned nose, facial nevi, large mouth and teeth, (C) profile portrait of the patient showing macrocephaly and posterior ear pits of the right helix. (D) CT scan of the patient at 16 years of age showing bilateral large cysts and a cystic nephroma in the remaining enlarged kidney. (E) Chest X-ray of the patient at 16 years of age showing left convex thoracic scoliosis. (F) dPCR results of DNA from skin biopsy from the patient. Blue cluster represents amplification of the target region—the mutant allele c.4031C>T. Red signals represent the internal reference control and green signals both mutant and reference alleles. Yellow cluster represents the wells where no amplification signal was detected. (G) Mutant frequency comparison. X-axis and Y-axis show the intensities of signals VIC and FAM channels. Columns display the distribution of 50% of the c.4031C>T variant in DNA from skin and blood from the patient. Left column—skin, right column—peripheral blood.

MATERIALS AND METHODS

Methods

Genomic DNA was extracted from peripheral blood, skin, saliva, oral mucosa, fresh tumour tissue and formalin-fixed, paraffin-embedded tumour tissue using standard protocols. DNA from both parents was extracted from peripheral blood.

Sequencing and bioinformatic analysis

Standard 30x whole genome sequencing (WGS), exome sequencing (ES) and bioinformatic analysis were performed at Clinical Genomics, SciLifeLab, Stockholm, using the Illumina HiSeq X Ten platform. Single nucleotide variants were called using Mutation Identification Pipeline. Variants were filtered, removing variants with a frequency over 1% in the general population.⁸ A constructed gene panel based on HPO-terms (Macrocephaly HP:0000256, Polydactyly HP:0010442,

Nephroblastoma HP:0002667) consisting of in total 476 genes were analysed regarding variants affecting coding regions or splicing (online supplemental table 1). The clinically relevant sequence variant was verified in the patient using Sanger sequencing. Carrier testing of the parents was performed using Sanger sequencing.

Digital PCR

Genomic DNA extracted from blood, skin, saliva and oral mucosa were amplified using 1X QuantStudio 3D Digital PCR Master mix and commercially available TaqMan assay for *DICER1* c.4031C>T mutation (Applied Biosystems, California, USA). DNA was quantified using Qubit fluorometry (Thermo Fisher Scientific, Massachusetts, USA). Then 14.6 μ L of PCR reaction mixes were loaded into QS3D Digital 20K V2 chips (Applied Biosystems). Protocol was followed as previously described.⁹ Digital PCR data were analysed using PoissonPlus algorithm (V.4.4.10) with a 95% CI and a desired precision of 10% by QuantStudio 3D AnalysisSuite (V.3.1.2-PRC-build-03).

RESULTS

Clinical description

The patient is the first child from healthy, non-consanguineous parents with unremarkable family history. He was born at gestational week 39 after a difficult delivery due to macrocephaly (Apgar 1-3-7). The birth weight was 3752 g, length 53 cm and head circumference 42 cm (>99th percentile). Clinical findings at birth included two blood vessels in the umbilical cord, undescended testis, inguinal hernia, postaxial polydactyly, ear pits and rocker bottom feet. Fontanel closure was late and he had difficulties breast feeding. At 15 months of age, he was diagnosed with a right-sided Wilms tumour (classic triphasic nephroblastoma with all three classic histological elements). Abdominal ultrasound also revealed a cyst of benign appearance in his left kidney. A lung scan showed multiple large cysts and a suspected Wilms tumour metastasis. A lobectomy of the middle lobe was performed to remove the tumour and three cysts. Owing to suspicion of additional metastasis, another thoracotomy was performed and two cysts in the right lower lobe were removed. The five removed lung cysts were diagnosed as benign fibrotic emphysematous alterations with bullous, cystic character. The pathologic-anatomic diagnosis of the lesion in the middle lobe was initially Wilms tumour metastasis, but following the identification of the pathogenic germline *DICER1* variant, pathology review determined that the correct diagnosis was well-differentiated fetal adenocarcinoma. Re-examination of radiographic findings, also after the *DICER1* syndrome diagnosis, revealed a suspicion of a multi-loculated cystic nephroma in the remaining kidney. The patient received postoperative chemotherapy and has been tumor-free since 2006. He had a late psychomotor development, started to walk at 3 years of age and spoke full sentences at 5 years. MRI of the brain was performed at 12 years of age and revealed signs of white matter reduction including a thin corpus callosum. At 18 years of age, he has normal length and weight, and a pronounced macrocephaly (>99th percentile). Dysmorphic features include a broad and furrowed forehead, wide mouth, tooth anomalies, doughy, soft skin and multiple nevi. Furthermore, he has ID, autism, behavioural problems and has required surgical treatment due to a left-convex thoracic scoliosis (figure 1, table 1).

Genetic findings

WGS analysis after bioinformatic filtering revealed four sequence variants for clinical review (online supplemental table 2). The

Table 1 All known patients with germline or mosaic RNase III domain hotspot mutations

DICER1 syndrome/phenotype	Klein et al ⁶ Pat 1	Klein et al. Pat 2	Rehder et al (this present study) ⁶	de Kock et al. ⁶ (Breneman et al ¹¹ Pat 102)	de Kock et al. ⁶ (Breneman et al ¹¹ Pat 105)	de Kock et al. ⁶ Pat 3	de Kock et al. ⁶ Pat 12	Breneman et al ¹¹ Pat 101	Breneman et al ¹¹ Pat 103	Breneman et al ¹¹ Pat 104	Breneman et al ¹¹ Pat 123
<p>Patient age and sex (if reported)</p> <p>DICER1 RNase III hotspot mutation: domain/germline or mosaic</p> <p>DICER1 RNase III hotspot mutation: tissue distribution and VAF</p> <p>DICER1 LOF mutation: tissue distribution (allele frequency)</p>	5 y M	14 m M	18 y M	10.9 y M	17.2 y F	6.8 y F	21 m M	9 y	14 y	13 y F	8 y
	c.5128G>T p.D1709Y RNase IIIb domain mosaic	c.401C>T p.S134L RNase IIIa domain germline	c.401C>T p.S134L RNase IIIa domain germline	c.5125G>A p.D1709N RNase IIIb domain mosaic	c.5427G>C p.E1813D RNase IIIb domain mosaic	c.5493C>C p.E1813D RNase IIIb domain mosaic	c.5125G>C p.D1709H RNase IIIb domain germline	c.5126A>G p.D1709G RNase IIIb domain mosaic	c.5125G>A, p.D1709N RNase IIIb domain mosaic	c.5428G>T, p.D1810Y RNase IIIb domain mosaic	c.5112G>A p.E1753K RNase IIIb domain mosaic
	Normal kidney (35%) Wilms tumour (37%)	Normal kidney (35%) Wilms tumour (47%)	Blood (50%) Skin (50%) Buccal cells (50%) Saliva (50%) Kidney tumour (8%) Lung tumour (8%)	Blood (4.6%) Skin (4.23%)–7.13%) Saliva (2.78%) Normal brain (11.52%) Uterus (10%) Kidney (17.7%) Type I PFB (34.24%) Type II PFB (43.84%) Brain PFB metastasis (14.97%)–31%)	Blood (0.04%) Urine (0.4%–0.66%) Saliva (0.25%–0.27%) Hair (0.24%) Lung cysts (9%) Lung cysts (10%) SCT (right) (76.8%–89.33%) SCT (left) (31.8%–44.48%) NCMH: (23.3%–30.55%)	Blood (0–0.04%) Normal right kidney #1: (3.26%–4.75%) Normal right kidney #2: (7.46%–14.55%) Cyst (right) (4.62%) Males developmental lesion right kidney (56.4%) Juvenile polyps (38.9%) NCMH: (27.35%)	Blood (heterozygous) Urine (0.02%) Saliva (0%–0.04%) Reactive lung (left) (0.35%–1%) Reactive lung (right) (6.93%–7.08%) Type I PFB (37.9%–37.84%)	Blood (NB) Normal lymph node (15.2%) Pituitary blastoma: (17.2%)	Blood (0.28%) CN: (14.9%) Type I PFB (16.2%) Small intestine polyps (17.2%)	Blood (0.21%) Normal Fallopian tube: (7.19%) Type I PFB (2.78%) SCT (29.2%) (24.2%) SCT (left): (92.4%)	Blood (ND) Normal ureter (13%) Type I PFB (24%) CN (35%)
	Blood (ND) Normal kidney (ND) Wilms tumour (33H) c.414-569A>G p.R1896G (variable)	Blood (ND) Kidney tumour: 0.61 Mb deletion (approx. 50%)	Blood (ND) PFB metastasis in brain: (allele loss)	Blood (ND) NCMH: (ND) Thyroid ca. (allele loss) SCT (right) (4.62%–46.2%) SCT (left) (4.62%–46.2%) (21.7%–44.8%) NCMH: c.4458_4458delA, p.K1886N(S*4 (NR))	Blood (ND) Reactive lung (ND) Type I PFB: c.1966C>T, p.R655* (NR) (allele loss)	Blood (ND) Pituitary blastoma: (allele loss)	Blood (ND) Pituitary blastoma: (allele loss)	Blood (ND) Normal lymph node: (ND)	Blood (ND) CN: c.1239G>A, p.V377I (3.1%) Type I PFB: c.1100G>A, p.W400* (allele loss) Small intestine polyp: c.98G>A, p.V32* (3%) c.1759A>A; p.G592M+15 (36.2%) SCT (left): (allele loss)	Blood (ND) Normal Fallopian tube: (ND) Type I PFB: (ND) SCT (right): (21.8%) SCT (left): (92.4%) c.1759A>A; p.G592M+15 (36.2%) SCT (left): (allele loss)	Blood (ND) Normal ureter: (ND) Type I PFB: (allele loss) CN (allele loss)
Intellectual impairment	DD	DD	ID	ND	ND	ND	ND	NR	NR	NR	NR
Autism	Yes	NR	Yes	NR	NR	NR	NR	NR	NR	NR	NR
Hypotonia	Yes	Yes	Yes	NR	NR	NR	NR	NR	NR	NR	NR
Overgrowth	Macrocephaly/Global	Macrocephaly	Macrocephaly	ND	NR	NR	NR	NR	NR	NR	NR
Birth weight	4904 g (>99th percentile)	2920 g (18th percentile)	3752 g (79th percentile)	4430 g (>99th percentile)	NR	NR	NR	NR	NR	NR	NR
Birth length	NR	NR	53 cm (95th percentile)	56 cm (>99th percentile)	NR	NR	NR	NR	NR	NR	NR
OF at birth	NR	NR	42 cm (>99th percentile)	42 cm (>99th percentile)	NR	NR	NR	NR	NR	NR	NR
Growth asymmetry: weight (kg)/length (L/head size) (OTC)	28 m: W 15.5 kg (91.9th percentile) L 95 cm (95.5th percentile) OTC 35 cm (>99th percentile)	14 m: W 15.5 kg (>99th percentile) L 81 cm (95.6th percentile) OTC 62 cm (>99th percentile)	18 y: W normal L normal L 112 cm (27.4th percentile)	6 y: W 15.8 kg (3.6th percentile) L 112 cm (27.4th percentile)	NR	NR	NR	NR	NR	NR	NR
Nephromegaly	Yes	NR	No	NR	NR	NR	NR	NR	NR	NR	NR
Renal cysts	Multiple small cysts	Multiple isolated cystic mass (left)	CN at 8 y	NR	Hamartomatous (but renal cysts at 1 y)	CN at 1 y	Yes	CN at 1 y, 3 m	CN at 1 y	CN at 1 y	CN at 1 y, 6 m
Lung cysts/PFB	Lung cysts/PFB	Lung cysts at 11 m	Type I PFB Type II PFB	Type I PFB Type II PFB	Benign/multifocal (but lung cysts at 1 y)	Type I PFB (right) Lung cysts (left)	Type II PFB	PFB at 1 y, 3 m	Type I PFB at 11 m	Type I PFB at 5 m	Type I PFB at 1 y, 6 m
Hyperkloron	Yes	(Yes)	Yes	NR	NR	NR	NR	NR	NR	NR	NR
Prominent forehead	Yes	Yes	Yes	NR	NR	NR	NR	NR	NR	NR	NR
Amniotic membranes	Yes	NR	Yes	NR	NR	NR	NR	NR	NR	NR	NR
Flat nasal bridge	Yes	Yes	Yes	NR	NR	NR	NR	NR	NR	NR	NR
Micrognathia	(Yes)	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
Macrosomia	NR	NR	Yes	NR	NR	NR	NR	NR	NR	NR	NR
Pits	Sacral dimple–climaxes on sides of ankles	Ear pit (left)	Ear pits, posterior heels (left)	NR	NR	NR	NR	NR	NR	NR	NR
Skin findings	Doughy hands Fat pads on feet Pronounced plantar creases	Soft skin Doughy soft hands Furrowed forehead Multiple nevi	NR	NR	NR	NR	NR	NR	NR	NR	NR
Skeletal abnormalities	Pectus excavatum Kyphosis	Scapulae Polydactyly	Narrow thorax Increased intermamillary distance Prominent sternum	NR	NR	NR	NR	NR	NR	NR	NR
Increased CSF space	Yes	Yes	Yes	NR	NR	NR	NR	NR	NR	NR	NR
Fontanel	Large anterior fontanel	NR	Late fontanel closure	NR	NR	NR	NR	NR	NR	NR	NR
Hernia	Inguinal and umbilical	Inguinal	Inguinal	NR	NR	NR	NR	NR	NR	NR	NR
Brain imaging	Enlarged lateral and third ventricles	Mild volume loss	Mild volume loss Hydrocephalus Cyst	Enlarged lateral ventricles Hydrocephalus	NR	NR	NR	NR	NR	NR	NR
Wilms tumour (age of Dx)	Bilateral 9m5y	Bilateral 1 y 1 m2 y 6 m	Unilateral 11 m	ND	ND	ND	ND	ND	ND	ND	ND

Continued

Table 1 Continued

DICER1 syndrome-phenotype	Klein et al. Pat. 1	Klein et al. Pat. 2	Ponkin et al (the present study)	Carlens et al. ⁶	de Kock et al. Pat. 1 (Bremner et al. ¹³ Pat. 102)	de Kock et al. Pat. 2 (Bremner et al. ¹³ Pat. 105)	de Kock et al. Pat. 3	de Kock et al. Pat. 12	Bremner et al. ¹³ Pat. 101	Bremner et al. ¹³ Pat. 103	Bremner et al. ¹³ Pat. 104	Bremner et al. ¹³ Pat. 123
Small intestine polyps	NR	NR	NR	NR	Yes	NR	Hamartomatous juvenile intestinal polyps at 6 m	NR	Yes	Yes	Yes	NR
Additional cysts or tumours	NR	NR	NR	NR	NCMH at 8 y Testicular cyst at birth PPB brain metastasis	NCMH at 15 y Pineoblastoma at 7 y Follicular papillary thyroid carcinoma at 10 y Bili.SLCT at 13 y and 15 y Clay body medulloblastoma at 17 y	NOHH at 6 y	Pluriary blastoma at 8 m	Hodgkin lymphoma at 7 y	Pelvic sarcoma at 14 y	SCT lilar at 5 y and 13 y Thyroid nodules at 7 y	NR
Other clinical findings	Respiratory distress	Pre-eclampsia in mother	Reduced fetal movement during pregnancy Recent testis torsion Large teeth Large nose Large blood vessels in umbilical cord Large spleen Polymorphous melanoid after scoliosis surgery	Low set ears Pulmonary infections Myopathic facies with ptosis and open mouth	Social web at birth Enferic optic profunda at 8 m	Left ocular pre-tissical changes, vascular mass Recurrent retinal detachment	Renal medullary malformation with disorganised collecting system and dilated lymphatic vessels	NR	NR	NR	NR	NR

CL, cleft lip; CP, cleft palate; IMR, intestinal malrotation; NCMH, non-communicating hydrocephalus; NOHH, non-obstructive hydrocephalus; NS, non-specific; ODC, oesophageal diverticulum; PPH, postnatal polyhydramnios; SCL, sclerotic lymphoid cyst; SCT, sclerotic cyst; SLE, systemic lupus erythematosus; ST, strabismic squint; TM, torticollis; TMS, torticollis; VSD, ventricular septal defect; WNT, winged scapula; YL, yolk sac tumour.

only clinically relevant variant was a heterozygous sequence variant in exon 21 of *DICER1*; NM_030621.4: c.4031C>T, (p.S1344L). The variant was verified and segregation analysis was performed using Sanger sequencing. Neither of the parents were carriers of this variant (data not shown). Digital PCR was performed on patient-DNA from buccal cells (not shown), saliva (not shown), blood and skin (**figure 1**), which showed a mutant allelic frequency of 50% in all samples, thus excluding mosaicism of the mutation. ES of DNA prepared from kidney and lung tumour tissue revealed that the germline heterozygous mutation c.4031C>T in *DICER1* was more abundant in the tumour tissue, 87% and 90%, respectively. In order to verify loss of heterozygosity (LOH) in the tumour, DNA from the fresh tissue (kidney tumour) was subjected to WGS. WGS data confirmed a 0.61 Mb deletion covering the whole *DICER1* gene (Chr14(Hg19): g.95247243_95858197del).

ES of the well-differentiated fetal lung adenocarcinoma revealed distinct tumour-only single nucleotide variants that distinguished it from the Wilms tumour and confirmed its separate nature.

DISCUSSION

We show that a heterozygous germline mutation c.4031C>T (p.S1344L) in the RNase IIIa domain of *DICER1* is compatible with life, and causes a complex ‘DICER1 syndrome plus’ phenotype with extensive bilateral and multilobar lung cysts, PPB, cystic nephroma, Wilms tumour, well-differentiated fetal lung adenocarcinoma, ID, macrocephaly, ear pits and other physical anomalies. This phenotype closely resembles reported clinical findings of a patient with the identical germline p.S1344L pathogenic variant presented at a paediatric pneumology association meeting in Vienna.¹⁰ There are also close similarities to the phenotype described in two children with GLOW syndrome and mosaic hotspot mutations in the RNase IIIb domain,⁵ although the postnatal overgrowth was more pronounced in the individuals with GLOW syndrome. Thus, the phenotype of the widely expressed germline RNase IIIa-S1344L variant resembles the extreme end of the phenotypes associated with mosaic hotspot mutations in the sequence encoding the RNase IIIb domain of *DICER1*.¹¹ This strongly supports previous somatic findings from integrated genetic analysis and in vitro cell experiments in cancer cells, where the RNase IIIa-S1344L mutation functionally perturbs RNase IIIb catalytic activity.^{2,4} The observation that only a minority of reported germline (n=1) or mosaic (n=10) RNase IIIb mutations are associated with the so-called GLOW phenotype (**table 1**), suggests that these mutations result in severe but highly pleiotropic phenotypes that cannot be predicted from the genotype.^{2,5,6,11} It will be important to determine whether, in contrast, RNase IIIa hotspot mutations invariably result in a severe ‘DICER1 syndrome plus’ phenotype.

In support of a potentially distinct functional consequence of RNase IIIa hotspot mutations, compared with RNase IIIb mutations, RNase IIIa catalytic site mutations are rare in cancers and RNase IIIa-S1344L is the only recurring cancer hotspot mutation that occurs in this domain. To date, p.S1344L mutations have been described in 15 tumours. Interestingly, the types of tumours which develop due to *DICER1* hotspot mutations are unevenly distributed among the targeted tissues. In the 15 tumours with p.S1344L in the RNase IIIa domain, there were 4 Wilms tumours, 4 malignant melanomas, 1 Merkel cell carcinoma, 3 endometrioid carcinomas, 2 colorectal cancers and 1 cholangiocarcinoma.^{10,12–15} Tumours bearing RNase IIIa-S1344L hotspot mutations are most commonly malignant melanomas

(4/15; 27%) in contrast to tumours bearing hotspot mutations in the RNase IIIb domain (2/318; 0.6%).^{4,15} This indicates that hotspot mutations in different RNase III domains of DICER1 cause tissue-specific susceptibilities to develop certain tumours.

This is the second well-differentiated fetal lung adenocarcinoma reported in DICER1 syndrome.^{16–18} Here, the diagnosis was made on the basis of glycogen-rich neoplastic glands and tubules resembling fetal lung tissue (at 10–15 weeks gestation). In contrast to biphasic PPB, the adjacent stroma is benign.

In addition to our patient, we identified 27 sequenced Wilms tumours with RNase IIIa or RNase IIIb domain hotspot mutations; in 17 of 28 (61%) there was no alteration on the other allele, while 11 of 28 (39%) had two mutations. One tumour with a germline RNase IIIa hotspot mutation did not undergo somatic testing (online supplemental table 3). Further studies are needed to determine if the sequenced Wilms tumours that lacked somatic alterations on the other allele could have copy neutral LOH or a deletion as described in our patient, or other genetic aberrations that escaped detection by the methods used.

Non-tumour-related phenotypes occur in DICER1 syndrome; macrocephaly has recently been described in 28/67 (42%) of patients with the syndrome in a single study.¹⁹ General overgrowth is more pronounced in patients with GLOW syndrome,⁵ while patients with RNase IIIa-S1344L mutations only present with macrocephaly.¹⁰ Recently, Klein *et al* reported activation of the phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway in genetically modified cells with hotspot mutations in the RNase IIIb domain associated with GLOW syndrome.²⁰ It is noteworthy that some patients with mutations in the PI3K/AKT/mTOR pathway have overlapping symptoms with our patient, such as polydactyly in patients with mutations in *AKT3* or *PIK3CA*, and multiple nevi, macrocephaly and ID seen in *PTEN* and *PIK3CA*-related disorders. Posterior helical pits are rare and have previously been described in Beckwith-Wiedemann syndrome, Simpson-Golabi-Behmel syndrome and GLOW syndrome, all of which are cancer predisposition syndromes with a risk of developing Wilms tumour. In patients with Beckwith-Wiedemann syndrome and *CDKN1C* mutations, an extended phenotype including ear pits and polydactyly has been described. To date, ID/developmental delay has been reported in at least nine patients with large deletions encompassing several genes including *DICER1*,^{21–27} and in three patients with RNase IIIb or RNase IIIa-S1344L hotspot mutations.^{5,10}

The highly penetrant and severe phenotypes described in patients with germline or mosaic RNase III domain mutations^{5,6} may be explained by the likelihood of a second somatic mutation stochastically occurring in any part of *DICER1* being greater than the reverse succession normally seen in DICER1 syndrome, in combination with tissue-specific neomorphic effects of the specific heterozygous RNase III domain mutations.¹¹

In conclusion, germline RNase IIIa-S1344L pathogenic variants result in a "DICER1 syndrome plus" phenotype that in addition to classic features, also includes ID and ear pits. The conferred phenotype is similar, but not identical to that of early post zygotic DICER1 RNase IIIb hotspot mutations.

Acknowledgements The authors would like to thank the family of the described patient for their participation. Additional results published here are in part based on data generated by the TCGA Research Network: <https://www.cancer.gov/tcga>.

Contributors AN coordinated the study. AN and KLR performed WGS analyses. NP provided clinical care. SW, SF, WDF, AN and NP performed clinical and pathological phenotyping. SF and FT performed digital PCR. EP, SF, FT, AN, RV, NP, WDF, LdK and KLR contributed with data collection, interpretation and discussion of results. EP and AN wrote the manuscript in consultation with all authors.

Funding This work was supported by grants from the Swedish Childhood Cancer Fund, the Swedish Cancer Society, the Cancer Society of Stockholm, the Swedish Research Council, Berth von Kantzow's Foundation and The Hällsten Research Foundation.

Competing interests WDF reports support from AstraZeneca, outside the submitted work (VUS classification project in breast cancer gene sequencing project).

Patient consent for publication Parental/guardian consent obtained.

Ethics approval The local Ethics Committee at Karolinska Institute approved the study (Dnr 2012-2106-31/4), which followed the tenets of the Declaration of Helsinki. Written informed consent was obtained from the parents.

Provenance and peer review Not commissioned; externally peer reviewed.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: <https://creativecommons.org/licenses/by/4.0/>.

ORCID iDs

Emeli Pontén <http://orcid.org/0000-0002-9174-9804>
 Fulya Taylan <http://orcid.org/0000-0002-2907-0235>
 Leanne de Kock <http://orcid.org/0000-0001-7314-1371>
 William D Foulkes <http://orcid.org/0000-0001-7427-4651>
 Kristina Lagerstedt-Robinson <http://orcid.org/0000-0001-9848-0468>
 Ann Nordgren <http://orcid.org/0000-0003-3285-4281>

REFERENCES

- Foulkes WD, Priest JR, Duchaine TF. DICER1: mutations, microRNAs and mechanisms. *Nat Rev Cancer* 2014;14:662–72.
- de Kock L, Wu MK, Foulkes WD. Ten years of DICER1 mutations: Provenance, distribution, and associated phenotypes. *Hum Mutat* 2019;40:1939–53.
- Rakheja D, Chen KS, Liu Y, Shukla AA, Schmid V, Chang T-C, Khokhar S, Wickiser JE, Karandikar NJ, Malter JS, Mendell JT, Amatruda JF. Somatic mutations in Drosha and DICER1 impair microRNA biogenesis through distinct mechanisms in Wilms tumours. *Nat Commun* 2014;2:4802.
- Vedanayagam J, Chatila WK, Aksoy BA, Majumdar S, Skanderup AJ, Demir E, Schultz N, Sander C, Lai EC. Cancer-Associated mutations in DICER1 RNase IIIA and IIIB domains exert similar effects on miRNA biogenesis. *Nat Commun* 2019;10:3682.
- Klein S, Lee H, Ghahremani S, Kempert P, Ischander M, Teitell MA, Nelson SF, Martinez-Agosto JA. Expanding the phenotype of mutations in DICER1: mosaic missense mutations in the RNase IIIB domain of DICER1 cause glow syndrome. *J Med Genet* 2014;51:294–302.
- de Kock L, Wang YC, Revil T, Badescu D, Rivera B, Sabbaghian N, Wu M, Weber E, Sandoval C, Hopman SMJ, Merks JHM, van Hagen JM, Bouts AHM, Plager DA, Ramasubramanian A, Forsmark L, Doyle KL, Toler T, Callahan J, Engelenberg C, Bouron-Dal Soglio D, Priest JR, Ragoussis J, Foulkes WD. High-sensitivity sequencing reveals multi-organ somatic mosaicism causing DICER1 syndrome. *J Med Genet* 2016;53:43–52.
- de Kock L, Sabbaghian N, Plourde F, Srivastava A, Weber E, Bouron-Dal Soglio D, Hamel N, Choi JH, Park S-H, Deal CL, Kelsey MM, Dishop MK, Esbenshade A, Kuttesch JF, Jacques TS, Perry A, Leichter H, Maeder P, Brundler M-A, Warner J, Neal J, Zacharin M, Korbonits M, Cole T, Traunecker H, McLean TW, Rotondo F, Lepage P, Albrecht S, Horvath E, Kovacs K, Priest JR, Foulkes WD. Pituitary blastoma: a pathognomonic feature of germ-line DICER1 mutations. *Acta Neuropathol* 2014;128:111–22.
- Karczewski KJ, Francioli LC, Tiao G, Cummings BB, Alfoldi J, Wang Q, Collins RL, Laricchia KM, Ganna A, Birnbaum DP, Gauthier LD, Brand H, Solomonson M, Watts NA, Rhodes D, Singer-Berk M, England EM, Seaby EG, Kosmicki JA, Walters KR, Tashman K, Farjoun Y, Banks E, Poterba T, Wang A, Seed C, Whiffin N, Chong JX, Samocha KE, Pierce-Hoffman E, Zappala Z, O'Donnell-Luria AH, Minikel EV, Weisburd B, Lek M, Ware JS, Vittal C, Armean IM, Bergelson L, Cibulskis K, Connolly KM, Covarrubias M, Donnelly S, Ferriera S, Gabriel S, Gentry J, Gupta N, Jeandet T, Kaplan D, Llanwarne C, Munshi R, Novod S, Petrillo N, Roazen D, Ruano-Rubio V, Saltzman A, Schleicher M, Soto J, Tibbetts K, Tolonen C, Wade G, Talkowski ME, Neale BM, Daly MJ, MacArthur DG, Genome Aggregation Database Consortium. The mutational constraint spectrum quantified from variation in 141,456 humans. *Nature* 2020;581:434–43.

- 9 Frisk S, Taylan F, Blaszczyk I, Nennesmo I, Annerén G, Herm B, Stattin E-L, Zachariadis V, Lindstrand A, Tesi B, Laurell T, Nordgren A. Early activating somatic PIK3CA mutations promote ectopic muscle development and upper limb overgrowth. *Clin Genet* 2019;96:118–25.
- 10 Carlens J KC, Ahrens F, Griese M, Schwerk N. *Zeitschrift der gesellschaft für pädiatrische pneumologie*, 2018: 36–41.
- 11 Brenneman M, Field A, Yang J, Williams G, Doros L, Rossi C, Schultz KA, Rosenberg A, Ivanovich J, Turner J, Gordish-Dressman H, Stewart D, Yu W, Harris A, Schoettler P, Goodfellow P, Dehner L, Messinger Y, Hill DA. Temporal order of RNase IIIb and loss-of-function mutations during development determines phenotype in pleuropulmonary blastoma / *DICER1* syndrome: a unique variant of the two-hit tumor suppression model. *F1000Res* 2015;4.
- 12 Gadd S, Huff V, Walz AL, Ooms AHAG, Armstrong AE, Gerhard DS, Smith MA, Auvil JMG, Meerzaman D, Chen Q-R, Hsu CH, Yan C, Nguyen C, Hu Y, Hermida LC, Davidsen T, Gesuwan P, Ma Y, Zong Z, Mungall AJ, Moore RA, Marra MA, Dome JS, Mullighan CG, Ma J, Wheeler DA, Hampton OA, Ross N, Gastier-Foster JM, Arold ST, Perlman EJ. A children's Oncology group and target initiative exploring the genetic landscape of Wilms tumor. *Nat Genet* 2017;49:1487–94.
- 13 Wu MK, Sabbaghian N, Xu B, Addidou-Kalucki S, Bernard C, Zou D, Reeve AE, Eccles MR, Cole C, Choong CS, Charles A, Tan TY, Iglesias DM, Goodyer PR, Foulkes WD. Biallelic *DICER1* mutations occur in Wilms tumours. *J Pathol* 2013;230:154–64.
- 14 Zehir A, Benayed R, Shah RH, Syed A, Middha S, Kim HR, Srinivasan P, Gao J, Chakravarty D, Devlin SM, Hellmann MD, Barron DA, Schram AM, Hameed M, Dogan S, Ross DS, Hechtman JF, DeLair DF, Yao J, Mandelker DL, Cheng DT, Chandramohan R, Mohanty AS, Ptashkin RN, Jayakumar G, Prasad M, Syed MH, Rema AB, Liu ZY, Nafa K, Borsu L, Sadowska J, Casanova J, Bacares R, Kiecka IJ, Razumova A, Son JB, Stewart L, Baldi T, Mullaney KA, Al-Ahmadie H, Vakiani E, Abeshouse AA, Penson AV, Jonsson P, Camacho N, Chang MT, Won HH, Gross BE, Kundra R, Heins ZJ, Chen H-W, Phillips S, Zhang H, Wang J, Ochoa A, Wills J, Eubank M, Thomas SB, Gardos SM, Reales DN, Galle J, Durany R, Cambria R, Abida W, Cercek A, Feldman DR, Gounder MM, Hakimi AA, Harding JJ, Iyer G, Janjigian YY, Jordan EJ, Kelly CM, Lowery MA, Morris LGT, Omuro AM, Raj N, Razavi P, Shoushtari AN, Shukla N, Soumerai TE, Varghese AM, Yaeger R, Coleman J, Bochner B, Riely GJ, Saltz LB, Scher HI, Sabbatini PJ, Robson ME, Klimstra DS, Taylor BS, Baselga J, Schultz N, Hyman DM, Arcila ME, Solit DB, Ladanyi M, Berger MF. Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. *Nat Med* 2017;23:703–13.
- 15 Tate JG, Bamford S, Jubb HC, Sondka Z, Beare DM, Bindal N, Boutselakis H, Cole CG, Creatore C, Dawson E, Fish P, Harsha B, Hathaway C, Jupe SC, Kok CY, Noble K, Ponting L, Ramshaw CC, Rye CE, Speedy HE, Stefancsik R, Thompson SL, Wang S, Ward S, Campbell PJ, Forbes SA. Cosmic: the Catalogue of somatic mutations in cancer. *Nucleic Acids Res* 2019;47:D941–7.
- 16 de Kock L, Bah I, Wu Y, Xie M, Priest JR, Foulkes WD. Germline and somatic *DICER1* mutations in a well-differentiated fetal adenocarcinoma of the lung. *J Thorac Oncol* 2016;11:e31–3.
- 17 Wu Y, Chen D, Li Y, Bian L, Ma T, Xie M. *DICER1* mutations in a patient with an ovarian Sertoli-Leydig tumor, well-differentiated fetal adenocarcinoma of the lung, and familial multinodular goiter. *Eur J Med Genet* 2014;57:621–5.
- 18 Liu S, Wang J, Luo X, Li X, Miao Y, Wang L, Li Q, Qiu X, Wang E-H. Coexistence of low-grade fetal adenocarcinoma and adenocarcinoma in situ of the lung harboring different genetic mutations: a case report and review of literature. *Oncotargets Ther* 2020;13:6675–80.
- 19 Khan NE, Bauer AJ, Doros L, Schultz KAP, Decastro RM, Harney LA, Kase RG, Carr AG, Harris AK, Williams GM, Dehner LP, Messinger YH, Stewart DR. Macrocephaly associated with the *DICER1* syndrome. *Genet Med* 2017;19:244–8.
- 20 Klein SD, Martinez-Agosto JA. Hotspot mutations in *DICER1* causing GLOW Syndrome-associated macrocephaly via modulation of specific microRNA populations results in activation of PI3K/ATK/mTOR signaling. *Microna* 2020;9:70–80.
- 21 de Kock L, Hillmer M, Wagener R, Soglio DB-D, Sabbaghian N, Siebert R, Priest JR, Miller M, Foulkes WD. Further evidence that full gene deletions of *DICER1* predispose to *DICER1* syndrome. *Genes Chromosomes Cancer* 2019;58:602–4.
- 22 HERRIGES JC, Brown S, Longhurst M, Ozmore J, Moeschler JB, Janze A, Meck J, South ST, Andersen EF. Identification of two 14q32 deletions involving *DICER1* associated with the development of *DICER1*-related tumors. *Eur J Med Genet* 2019;62:9–14.
- 23 de Kock L, Geoffrion D, Rivera B, Wagener R, Sabbaghian N, Bens S, Ellezam B, Bouron-Dal Soglio D, Ordóñez J, Sacharow S, Polo Nieto JF, Guilleman RP, Vujanic GM, Priest JR, Siebert R, Foulkes WD. Multiple *DICER1*-related tumors in a child with a large interstitial 14q32 deletion. *Genes Chromosomes Cancer* 2018;57:223–30.
- 24 van Engelen K, Villani A, Wasserman JD, Aronoff L, Greer M-LC, Tijerin Bueno M, Gallinger B, Kim RH, Grant R, Meyn MS, Malkin D, Druker H. *Dicer1* syndrome: approach to testing and management at a large pediatric tertiary care center. *Pediatr Blood Cancer* 2018;65.
- 25 Zampini L, D'Odorico L, Zanchi P, Zollino M, Neri G. Linguistic and psychomotor development in children with chromosome 14 deletions. *Clin Linguist Phon* 2012;26:962–74.
- 26 Ting TW, Brett MS, Cham BWM, Lim J-Y, Law HY, Tan EC, Lai AHM, Jamuar SS. *DICER1* deletion and 14q32 microdeletion syndrome: an additional case and a review of the literature. *Clin Dysmorphol* 2016;25:37–40.
- 27 Piccione M, Antona V, Scavone V, Malacarne M, Pierluigi M, Grasso M, Corsello G. Array CGH defined interstitial deletion on chromosome 14: a new case. *Eur J Pediatr* 2010;169:845–51.